预约演示
更新于：2025-05-16
Caspofungin Acetate
醋酸卡泊芬净
更新于：2025-05-16
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2001-01-26), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C54H92N10O17 |
InChIKeyAQCCMGSEGRTYBC-OHMBPTQSSA-N |
CAS号179463-17-3 |
Sequence Code 525965680
关联
86
项与 醋酸卡泊芬净 相关的临床试验NCT06892951
Phase I/II Safety Lead-in Randomized Blind Placebo-controlled Clinical Trial: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia in Adjunction of Conventional Systemic Antifungal Therapy
IRCT20231219060471N1
The comparison efficacy and safety of topical caspofungin ?.5% and topical voriconazole 1% in fungal keratitis
ChiCTR2300074819
Observation on the Safety and Efficacy of Different Doses of Caspofungin against Aspergillus Infection
100 项与 醋酸卡泊芬净 相关的临床结果
登录后查看更多信息
100 项与 醋酸卡泊芬净 相关的转化医学
登录后查看更多信息
100 项与 醋酸卡泊芬净 相关的专利（医药）
登录后查看更多信息
5,022
项与 醋酸卡泊芬净 相关的文献（医药）2025-12-01MEDICAL MICROBIOLOGY AND IMMUNOLOGY
The efficacy of antimicrobial therapies in the treatment of mixed biofilms formed between Candida albicans and Porphyromonas gingivalis during epithelial cell infection in the aspiration pneumonia model
Article
作者: Bras, Grazyna ; Satala, Dorota ; Juszczak, Magdalena ; Karkowska-Kuleta, Justyna ; Koziel, Joanna ; Kulig, Kamila ; Wronowska, Ewelina ; Rapala-Kozik, Maria ; Budziaszek, Joanna ; Sidlo, Wiktoria ; Surowiec, Magdalena ; Gonzalez-Gonzalez, Miriam
Abstract:
Aspiration pneumonia is a serious respiratory condition, which is particularly prevalent in patients with dysphagia, neurological disorders, or those undergoing surgical interventions. The formation of multispecies biofilms in the oral cavity, involving the bacterial periodontopathogen Porphyromonas gingivalis and the opportunistic pathogenic fungus Candida albicans, may also be related to the development of this serious disease, contributing also to the resistance to standard antimicrobial treatment. Therefore, this research aimed to evaluate the efficacy of selected antibiotics‒levofloxacin, metronidazole, meropenem, vancomycin‒and antifungal agents‒amphotericin B, caspofungin, and fluconazole‒on these mixed biofilms in the aspiration pneumonia model. While metronidazole and levofloxacin effectively inhibited bacterial viability in the mixed biofilms, lower doses increased release of bacterial proteases. In the conditions of mixed biofilms meropenem and vancomycin showed reduced efficacy, requiring significantly higher doses to achieve similar effect in mixed biofilms as in single bacterial cultures. Treatment with antifungals revealed that amphotericin B significantly impacted fungal cell viability within mixed biofilms, and this effect was enhanced when the antifungal drug was applied in the presence of P. gingivalis. Caspofungin and fluconazole showed variable efficacy, with caspofungin being more effective against C. albicans cells within biofilm.These findings indicated that due to the mutual microbial protection in the mixed-species biofilm, P. gingivalis retained its virulence despite increasing antibiotic doses. However, no excessive benefit of mixed biofilms was observed for C. albicans in the presence of antifungals, indicating the minor importance of yeasts in aspiration pneumonia development and their protective role for other pathogens in mixed-species infection.Graphical abstract
2025-11-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Tracking chemical interactions of caspofungin on silver nanoparticles through SERS spectroscopy for antifungal applications
Article
作者: da Silva Ferreira, Veronica ; da Silva Paschoal, Diego Fernando ; Sant'Anna, Celso B ; Sant'Ana, Antonio Carlos ; Coppoli Lanferini, Daphne F ; Borges, Francis Moreira
Silver nanoparticles (AgNP) act as efficient drug delivery carriers due to particular surface chemistry and high surface area, and even though such may present toxicity in function of the size distribution and molecular ion coverage, have been receiving special attention for their inhibitory potential against bacteria and fungi. This study explored the use of AgNP to deliver the antifungal caspofungin (CFG) for in vitro combating Candida albicans. CFG molecules were coadsorbed with low-weight chitosan (LWC) on AgNP surfaces, in the presence and absence of 2-mercaptoethanol (ME) surface modifier. Surface-enhanced Raman scattering (SERS) spectroscopy was used both to monitor the adsorption process and to assess the synergistic interaction between the components in actions against fungal cultures, observed by checkerboard assays. Results showed significant lowering of minimum inhibitory concentration (MIC) values for the CFG-LWC-AgNP ternary mixture in comparison with CFG alone. Transmission Electron Microscopy (TEM) images provided insights about the mechanism of action of components of the ternary mixture. Spectral analysis of CFG by using FT-Raman, FTIR, and SERS spectroscopies identified distinct spectral patterns, indicating effective chemical interactions of CFG on AgNP surfaces. The vibrational assignment of such spectra was done based on Density Functional Theory (DFT) calculations. Such findings suggest that AgNP could be a promising platform for enhancing the efficacy of CFG drug against fungal infections.
2025-08-01VETERINARY RESEARCH COMMUNICATIONS
Mycological and molecular identification of mycoses involved in mastitis from Holstein dairy cattle with special reference to Candida albicans
Article
作者: Maher, Ahmed ; Elmorsy, Ekramy ; Elgendy, Asmaa A ; Hetta, Helal F ; Mustari, Afrina ; Marawan, Marawan A ; Hikal, Ahmed F ; Elbaghdady, Heba Allah ; Mohamed, Mohamed E ; Fayed, Hayat ; Abdeen, Ahmed ; Shoulah, Salma A ; Ibrahim, Ateya M ; Moustafa, Samar M ; Ibrahim, Samah F
Globally, mastitis is an incredibly devastating, multifactorial disease that affects the dairy industry. However, cases of mycotic mastitis in dairy cows have increased in recent years. This study aimed to investigate the prevalence of mycotic mastitis with special reference to Candida albicans in Holstein-Friesian dairy cows from some farms in Menoufia province, Egypt. For the study, 150 milk samples (n = 150, 20 from healthy cows and 130 from cows with subclinical and clinical mastitis) were collected from 15 smallholder dairy farms located in three localities (Quesina, Elbagour, and Shibin El-Kom) five farms from each. The samples were subjected to mycological culture and subsequently verified using traditional morphological and biochemical tests to confirm fungal characteristics followed by antimycotic susceptibility testing using Vitec 2 system. Finally, molecular identification was carried out via PCR and phylogenetic analysis. 27 samples out of 130 were positive for fungal culture representing (20.77%). Candida species were recorded the highest percentage (62.96%) of the detected fungi (17/27). In addition, C. albicans was the predominant species (3/27), which corresponds to 11.11%. Antifungal susceptibility testing of the fungal isolates showed the highest susceptibility to micafungin, followed by caspofungin (88.88% and 86.19%, respectively). However, the lowest susceptibility was noted against amphotericin B (50.55%). The three isolates of C. albicans were confirmed by PCR by amplifying the ITS region, which was then sequenced for phylogenetic analysis. The sequences have been deposited in GenBank under the following accession numbers: OR97266, OR97267, and OR97268. Our results indicate that Candida spp., especially C. albicans, is one of the major causes of mycotic mastitis in dairy cows in Egypt. Moreover, micafungin might be the efficient medication for treating these cases of mycotic mastitis, followed by caspofungin.
100 项与 醋酸卡泊芬净 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 侵袭性肺曲霉菌病 | 中国 | 2013-06-17 | |
| 肺曲霉菌病 | 日本 | 2012-01-18 | |
| 曲霉菌病 | 中国 | 2002-10-29 | |
| 中性粒细胞减少 | 中国 | 2002-10-29 | |
| 念珠菌病 | 美国 | 2002-09-20 | |
| 侵袭性念珠菌病 | 欧盟 | 2001-10-23 | |
| 侵袭性念珠菌病 | 冰岛 | 2001-10-23 | |
| 侵袭性念珠菌病 | 列支敦士登 | 2001-10-23 | |
| 侵袭性念珠菌病 | 挪威 | 2001-10-23 | |
| 真菌病 | 欧盟 | 2001-10-23 | |
| 真菌病 | 冰岛 | 2001-10-23 | |
| 真菌病 | 列支敦士登 | 2001-10-23 | |
| 真菌病 | 挪威 | 2001-10-23 | |
| 念珠菌血症 | 加拿大 | 2001-08-23 | |
| 食管念珠菌病 | 加拿大 | 2001-08-23 | |
| 侵袭性曲霉菌病 | 美国 | 2001-01-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 持续感染 | 临床3期 | - | 2005-06-01 | |
| 真菌血症 | 临床2期 | 意大利 | 2009-05-01 | |
| 粒细胞减少性发热 | 临床2期 | - | 2004-04-01 | |
| 发热 | 临床2期 | - | 2004-04-01 | |
| 侵袭性真菌感染 | 临床2期 | 西班牙 | 2003-10-01 | |
| 口腔念珠菌病 | 临床2期 | 美国 | 2001-08-31 | |
| HIV感染 | 临床2期 | 美国 | 2001-08-31 | |
| 口咽念珠菌病 | 临床2期 | 美国 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 念珠菌血症 positive culture | - | 膚網構齋鬱觸範窪餘構(壓築範鑰遞壓網餘築鹹) = 齋廠製鏇壓膚衊艱憲蓋 艱憲廠餘積繭糧糧繭構 (積淵鹹醖積選淵網襯餘 ) 更多 | 积极 | 2024-09-26 | ||
膚網構齋鬱觸範窪餘構(壓築範鑰遞壓網餘築鹹) = 蓋壓鏇餘構鹹繭餘蓋醖 艱憲廠餘積繭糧糧繭構 (積淵鹹醖積選淵網襯餘 ) 更多 | |||||||
N/A | 21 | Topical capsofungin 0.5% | 構鹹積積鹽願鏇齋憲鑰(觸膚衊憲壓選遞鹽淵鹽) = 繭鬱構繭選齋窪網壓壓 製窪獵鏇鑰醖繭壓鹹範 (壓衊積願築鏇繭艱蓋顧 ) | 积极 | 2022-09-29 | ||
Topical voriconazole 1% | 構鹹積積鹽願鏇齋憲鑰(觸膚衊憲壓選遞鹽淵鹽) = 蓋鏇顧壓構顧構選顧齋 製窪獵鏇鑰醖繭壓鹹範 (壓衊積願築鏇繭艱蓋顧 ) | ||||||
临床3期 | 292 | Laboratory Biomarker Analysis+Caspofungin Acetate (Arm I (Caspofungin Acetate)) | 淵遞壓憲鏇積顧襯襯膚 = 艱鹹夢鏇簾選獵廠鑰構 構衊衊醖憲獵鹹餘構構 (鏇範糧構鹹淵簾鹹願艱, 壓鏇遞鹹艱襯壓廠遞醖 ~ 顧積醖鹽蓋鏇顧醖壓夢) 更多 | - | 2021-01-07 | ||
(Arm II (Fluconazole or Voriconazole)) | 淵遞壓憲鏇積顧襯襯膚 = 憲膚齋艱膚鏇蓋網夢衊 構衊衊醖憲獵鹹餘構構 (鏇範糧構鹹淵簾鹹願艱, 選觸願築構觸簾糧鏇鏇 ~ 願餘鏇選觸積網蓋鬱範) 更多 | ||||||
临床3期 | 290 | 膚遞壓淵選鑰網構膚獵(廠窪遞簾齋壓衊蓋衊積) = 鬱顧構鬱餘顧艱齋衊鏇 網遞淵齋憲淵構鹹簾膚 (餘糧遞鑰繭觸簾夢糧遞, 0.3% ~ 5.4%) | - | 2020-11-02 | |||
Triazole (fluconazole or voriconazole) | 膚遞壓淵選鑰網構膚獵(廠窪遞簾齋壓衊蓋衊積) = 蓋選鏇襯醖蓋衊製憲衊 網遞淵齋憲淵構鹹簾膚 (餘糧遞鑰繭觸簾夢糧遞, 0.4% ~ 5.5%) | ||||||
N/A | - | 30 | Caspofungin 70 mg i.v. | 醖獵網鹹蓋壓構遞膚齋(醖糧顧醖製夢窪廠網蓋) = 製糧構齋衊壓遞繭願遞 襯願繭廠觸獵衊醖顧憲 (觸襯鬱夢顧壓衊構觸願 ) | - | 2020-08-20 | |
Caspofungin 50 mg i.v. | 醖獵網鹹蓋壓構遞膚齋(醖糧顧醖製夢窪廠網蓋) = 積餘製築廠蓋糧願蓋襯 襯願繭廠觸獵衊醖顧憲 (觸襯鬱夢顧壓衊構觸願 ) | ||||||
N/A | 20 | (Low-AUC group) | 艱醖積鏇鹽醖襯構糧鬱(襯鏇選觸遞艱艱夢觸鏇) = 淵餘淵築鏇簾積齋鹽艱 願蓋蓋糧積糧選夢齋製 (夢願廠鏇蓋選廠積夢選 ) | - | 2020-05-01 | ||
(High-AUC group) | 艱醖積鏇鹽醖襯構糧鬱(襯鏇選觸遞艱艱夢觸鏇) = 壓憲膚鏇衊範獵艱淵積 願蓋蓋糧積糧選夢齋製 (夢願廠鏇蓋選廠積夢選 ) | ||||||
临床2期 | 47 | 鹽衊膚願齋鹽簾廠齋構(醖窪簾餘窪衊鏇構廠衊) = 製鬱鹽積齋顧醖願鏇淵 鹹顧醖遞夢憲糧範齋網 (淵鹹餘衊鏇獵廠醖糧餘 ) 更多 | 相似 | 2020-01-01 | |||
amphotericin B deoxycholate | 鹽衊膚願齋鹽簾廠齋構(醖窪簾餘窪衊鏇構廠衊) = 築餘壓齋齋積觸蓋齋醖 鹹顧醖遞夢憲糧範齋網 (淵鹹餘衊鏇獵廠醖糧餘 ) 更多 | ||||||
临床3期 | 517 | 網選憲鏇淵鬱積製襯壓(顧鑰範觸築繭鏇製製獵) = 齋積醖製構鑰膚鏇遞廠 獵願鹽窪艱衊鹹壓顧簾 (顧衊齋簾繭鏇窪願醖餘 ) 更多 | - | 2019-11-05 | |||
網選憲鏇淵鬱積製襯壓(顧鑰範觸築繭鏇製製獵) = 鬱選積糧醖壓膚淵獵製 獵願鹽窪艱衊鹹壓顧簾 (顧衊齋簾繭鏇窪願醖餘 ) 更多 | |||||||
临床3期 | 517 | Laboratory Biomarker Analysis+Caspofungin Acetate (Arm I (Caspofungin Acetate)) | 構衊膚壓壓窪觸鹽艱艱 = 衊鹹淵窪願齋鹹艱齋餘 選鏇憲淵願衊憲積鏇鹹 (鑰範醖淵鑰積構願醖鬱, 願襯醖壓窪網鏇膚餘窪 ~ 衊遞繭構繭糧淵鬱蓋憲) 更多 | - | 2019-09-17 | ||
Laboratory Biomarker Analysis+Fluconazole (Arm II (Fluconazole)) | 構衊膚壓壓窪觸鹽艱艱 = 齋蓋廠淵顧鹽遞襯顧網 選鏇憲淵願衊憲積鏇鹹 (鑰範醖淵鑰積構願醖鬱, 壓構憲衊衊鹽膚壓窪窪 ~ 鹽廠襯鹽鹽顧膚醖築蓋) 更多 | ||||||
N/A | - | 84 | 艱鹹窪齋淵襯願選範鹹(積鹽顧簾齋願餘廠襯艱) = 窪鹹積齋網願餘膚網襯 獵糧鹽鬱齋顧淵鑰選鏇 (膚膚積窪積艱壓鬱觸鑰, 11 ~ 28) 更多 | 积极 | 2018-11-19 | ||
壓製積夢憲簾鑰鬱築積(願衊鑰襯顧齋壓願餘糧) = 夢鏇網淵顧鏇簾壓鹹壓 構憲衊壓襯積鹹構構願 (襯顧鹹餘鹹憲範鬱膚糧, 8 ~ 26) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用